[CAS NO. 17817-31-1] Desmethylglycitein
PRODUCTS SPECIFICATIONS [17817-31-1]
DESCRIPTION [17817-31-1]
Overview
| MDL | MFCD00016953 |
|---|---|
| Molecular Weight | 270.24 |
| Molecular Formula | C15H10O5 |
| SMILES | O=C1C(C2=CC=C(O)C=C2)=COC3=CC(O)=C(O)C=C13 |
Summary
Desmethylglycitein (4',6,7-Trihydroxyisoflavone), a metabolite of daidzein, sourced from Glycine max with antioxidant, and anti-cancer activities. Desmethylglycitein binds directly to CDK1 and CDK2 in vivo, resulting in the suppresses CDK1 and CDK2 activity [1] . Desmethylglycitein is a direct inhibitor of protein kinase C ( PKC )α, against solar UV (sUV)-induced matrix matrix metalloproteinase 1 ( MMP1 ) [2] . Desmethylglycitein binds to PI3K in an ATP competitive manner in the cytosol, where it inhibits the activity of PI3K and downstream signaling cascades, leading to the suppression of adipogenesis in 3T3-L1 preadipocytes [3] .
IC50 & Target
|
CDK1 |
CDK2 |
PKC |
In Vitro
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity
[1]
.
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells
[1]
.
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% )
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Viability Assay [1]
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 12.5, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Inhibited anchorage-dependent and -independent growth of HCT-116 cells. |
Western Blot Analysis [1]
| Cell Line: | HCT-116 and DLD1 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited CDK1,CDK2 expression. |
Cell Cycle Analysis [1]
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Induces cell cycle arrest of HCT-116 cells at S and G2/M phases. |
In Vivo
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells [1] |
| Dosage: | 5 or 25 mg/kg |
| Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days |
| Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 125 mg/mL ( 462.55 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.7004 mL | 18.5021 mL | 37.0041 mL |
| 5 mM | 0.7401 mL | 3.7004 mL | 7.4008 mL |
| 10 mM | 0.3700 mL | 1.8502 mL | 3.7004 mL |
References
- [1] Lee DE, et al. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2. Carcinogenesis. 2011 Apr;32(4):629-35.
- [2] Lim TG, et al. The daidzein metabolite, 6,7,4'-Trihydroxyisoflavone, is a novel inhibitor of PKCα in suppressing solar UV-induced matrix metalloproteinase 1. Int J Mol Sci. 2014 Nov 19;15(11):21419-32
- [3] Seo SG, et al. A metabolite of daidzein, 6,7,4'-trihydroxyisoflavone, suppresses adipogenesis in 3T3-L1 preadipocytes via ATP-competitive inhibition of PI3K.
Synonyms
